

## Top Stocks that Could Run Higher

We've done well with current opportunities.

Over the last few weeks, we highlighted:

Moderna (MRNA) at \$63.60. It would run to \$87.  
Alpha Pro Tech (APT) at \$13.14. It would run to \$20.63.  
Teladoc Health (TDOC) at \$189. It would run to \$218.50.  
Inovio Pharmaceuticals (INO) at \$20. It would run to \$26.82.  
Novavax Inc.(NVAX) at \$77. It would run to \$147.31.  
Fiverr International (FVRR) at \$75. It would run to \$80.

While many vaccine stocks have already exploded higher, there's still plenty of upside with them all, and the following stocks.

### Inovio Pharmaceuticals (INO)

While we've already recommended this stock, we believe there's further upside ahead.



Inovio Pharmaceuticals recently said that 94% of Phase 1 trial participants saw an overall immune response six weeks into the study after two doses of INO-4800. By week eight, INO-4800 was found to be safe and well-tolerated with no serious side effects.

In an animal study, INO-4800 showed full protection against the replication of the virus in infected mice, said the company. Going forward, Inovio Pharmaceuticals has plans to initiate Phase 2/3 efficacy trials once it receives regulatory approval.

“We look forward to urgently advancing INO-4800, as it is the only nucleic-acid based vaccine that is stable at room temperature for more than a year and does not require to be frozen in transport or for years of storage, which are important factors when implementing mass immunizations to battle the current pandemic,” said President and CEO Dr. J. Joseph Kim.

### BioNTech (BNTX) and Pfizer (PFE)

BNTX has been incredibly explosive, but the run may have only just begun.



The company, along with Pfizer just reported additional data from their experimental vaccine showing the vaccine was safe and induced an immune response in patients.

In addition, the U.S. FDA “fast tracked” their vaccines.

According to BioNTech, two of the company’s four investigational candidates from its BNT162 mRNA-based program being developed to help protect against the virus were “fast tracked.” Going forward, Pfizer and BioNTech expect to start the next phase of the vaccine trial later this month with 30,000 subjects. If successful, the two expect to have 100 million doses of the vaccine by the close of 2020, and more than 1.2 billion by the end of 2021.

“The FDA’s decision to grant these two vaccine candidates Fast Track designation signifies an important milestone in the efforts to develop a safe and effective vaccine against SARS-CoV-2,” said Peter Honig, Senior Vice President, Global Regulatory Affairs, Pfizer.

### Moderna Inc. (MRNA)

JP Morgan downgraded MRNA on valuation concerns earlier this week.



"This stock move itself isn't entirely surprising given the rapid execution on mRNA-1273, the tremendous widespread investor interest on this program, and the obvious unmet need/opportunity for a vaccine," noted the firm. "That said, at these levels we are having difficulty justifying more upside given the uncertainty of the duration/characteristics of the situation."

But with solid progress under its belt, MRNA could still push well above \$100 a share. In my opinion, the downgrade was foolish given the overwhelming demand for a vaccine, and the news momentum being generated.